Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for ARS Pharmaceuticals, Inc. (SPRY) despite higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - The consensus estimate predicts a quarterly loss of $0.41 per share, reflecting a year-over-year change of -215.4% [3]. - Expected revenues are projected at $15.12 million, which represents a significant increase of 2924% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst assessments [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is stronger for positive readings [9][10]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [10]. Historical Performance - In the last reported quarter, ARS Pharmaceuticals was expected to post a loss of $0.35 per share and matched this expectation with no surprise [14]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [15]. Conclusion - ARS Pharmaceuticals does not appear to be a strong candidate for an earnings beat based on current estimates and historical performance, but other factors should also be considered by investors [18].